Young Koog Cheon

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Yeo-Min Yun · 1 shared paper, 2025 · strength 0.28
   • Paper Clearance of TP53 Mutations in ctDNA Reflects Therapeutic Response in Advanced Pancreatic Cancer Patients. DOI 10.21873/anticanres.17836↗
2. Chan Sup Shim · 1 shared paper, 2014 · strength 0.06
   • Paper Elevated hemoglobin A1c levels are associated with worse survival in advanced pancreatic cancer patients with diabetes. DOI 10.5009/gnl.2014.8.2.205↗
3. Seung Woo Park · 1 shared paper, 2017 · strength 0.05
   • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
4. Si Young Song · 1 shared paper, 2017 · strength 0.05
   • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
5. Hee Seung Lee · 1 shared paper, 2017 · strength 0.05
   • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
6. Chang Duck Kim · 1 shared paper, 2017 · strength 0.05
   • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
7. Jong Ho Moon · 1 shared paper, 2017 · strength 0.05
   • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
8. Moon Jae Chung · 1 shared paper, 2017 · strength 0.05
   • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
9. Dong Uk Kim · 1 shared paper, 2017 · strength 0.05
   • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
10. Jeong Youp Park · 1 shared paper, 2017 · strength 0.05
    • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
11. Sang Hyub Lee · 1 shared paper, 2017 · strength 0.05
    • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
12. Kwang Bum Cho · 1 shared paper, 2017 · strength 0.05
    • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
13. Ho Gak Kim · 1 shared paper, 2017 · strength 0.05
    • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
14. Ho Soon Choi · 1 shared paper, 2017 · strength 0.05
    • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
15. Dong Ki Lee · 1 shared paper, 2017 · strength 0.05
    • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
16. Yong‐Tae Kim · 1 shared paper, 2017 · strength 0.05
    • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
17. Seungmin Bang · 1 shared paper, 2017 · strength 0.05
    • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗
18. Chang Min Cho · 1 shared paper, 2017 · strength 0.05
    • Paper A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-… DOI 10.1097/md.0000000000005702↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.